NCT00052416已完成1 期
Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
详细描述
OBJECTIVES:
- Determine the feasibility, in terms of toxicity and patient compliance, of thalidomide in patients with asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Determine the event-free and progression-free survival of patients treated with this drug.
- Determine disease response and time to next treatment in patients treated with this drug.
- Determine the quality of life of patients treated with this drug.
OUTLINE: Patients receive oral thalidomide once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, monthly during study, and at the end of the study.
PROJECTED ACCRUAL: A total of 30-36 patients will be accrued for this study within 2 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed indolent lymphoma or leukemia of one of the following subtypes:
- •Chronic lymphocytic leukemia
- •Follicular center lymphoma (grade I or II)
- •Lymphoplasmacytic lymphoma
- •Marginal zone lymphoma (nodal, extranodal, or splenic)
- •Small lymphocytic lymphoma
- •Waldenstrom's macroglobulinemia
- •Any stage of disease allowed
- •No hairy cell leukemia
- •No T-cell lymphomas
- •No prior treatment for lymphoma/leukemia
- •Considered appropriate for expectant management
- •Must not require cytotoxic therapy
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count at least 1,500/mm^3
- •Hemoglobin greater than 10.0 g/dL
- •Platelet count greater than 75,000/mm^3
- •Bilirubin no greater than 2 times normal
- •AST and ALT no greater than 2 times normal
- •Creatinine no greater than 2.0 mg/dL
- •Cardiovascular
- •No uncontrolled congestive heart failure
- •No New York Heart Association class III or IV heart disease
- •No unstable coronary artery disease
- •No myocardial infarction in the past 6 months
- •No serious or uncontrolled arrhythmias
- •No history of thromboembolic disease
- •No asthma or chronic obstructive pulmonary disease requiring the use of home oxygen or frequent oral steroids (prednisone greater than 20 mg per day for 5 days within the past 3 months)
- •HIV negative
- •Not pregnant or nursing
- •Negative pregnancy test
- •Not planning to become pregnant in the next 2 years
- •Fertile female patients must use 1 highly effective method and 1 additional effective method of contraception for 1 month prior to, during, and for 1 month after study participation
- •Male patients must use effective barrier contraception during and for 1 month after study participation
- •Willing and able to participate in the S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety) program
- •No contraindications to meeting the requirements of the S.T.E.P.S. program
- •No other prior malignancy except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix
- •No peripheral neuropathy
- •No poorly controlled diabetes defined by either of the following:
- •Glycosylated hemoglobin greater than 8.0 g/dL
- •Known end organ disease (i.e., nephropathy, retinopathy, or neuropathy)
- •No other concurrent illness that would preclude study therapy
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- 另有 8 项未显示
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Thalidomide and Docetaxel in Treating Patients With Advanced CancerCancerNCT00049296Case Comprehensive Cancer Center26
已完成
2 期
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerOvarian CancerNCT00016224Memorial Sloan Kettering Cancer Center
已完成
2 期
Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsGastrointestinal Carcinoid TumorIslet Cell TumorNeoplastic SyndromeLung CancerNCT00027638Memorial Sloan Kettering Cancer Center
已完成
2 期
Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00053300Case Comprehensive Cancer Center30
已完成
2 期
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix CancerCarcinoma of the AppendixColorectal CancerNCT00310076Wake Forest University Health Sciences29